RxDoctor Payments Data

Roberto Secaira, MD

Undefined Physician type · Tacoma, WANPI 1053461145

Payments from drug & device makers

$2,960in general payments, 2019–2025

Across 36 payments — averaging $82.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$617
  • Abiomed$554
  • Medtronic$538
  • Livanova USA, Inc.$273
  • Shockwave Medical, Inc$207
  • Boehringer Ingelheim$159
  • plus $611 from 6 others

What the payments were for

  • Food & beverage$2,960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few undefined physician type providers in Washingtonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$207,755
Medicare patients
1,058
Services billed
2,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban248$269,584
EliquisApixaban184$208,401
EntrestoSacubitril/Valsartan63$88,989
Repatha SureclickEvolocumab72$87,194
JardianceEmpagliflozin49$69,512
Praluent PenAlirocumab23$25,826
Atorvastatin Calcium732$9,560
Metoprolol Succinate387$6,524
Rosuvastatin Calcium220$4,580
Losartan Potassium346$3,572
Ezetimibe124$2,584
ClopidogrelClopidogrel Bisulfate151$2,135
Diltiazem 24hr Er (La)Diltiazem Hcl15$2,017
Amlodipine Besylate228$1,947
Isosorbide Mononitrate ErIsosorbide Mononitrate101$1,491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$74$208,401184 claims
Boehringer IngelheimJardiance$159$69,51249 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few undefined physician type providers in Washingtonon file to place this against a meaningful peer group, so we don't.

Other undefined physician type in Tacoma

Where these figures come from

Is this you, or does something look wrong? →